Aspirin to prevent cardio- vascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379 86. 388. Patrono C, Baigent C, Hirsh J, et al.Antiplatelet drugs:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:199S 233S. 389. Lincoff AM, LeNarz LA, Despotis GJ, et al. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT tri- als. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. Ann Thorac Surg. 2000;70:516 26. 390. Berger PB, Steinhubl S. Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation. 2002;106:2284 7. 391. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus stan- dard-dose clopidogrel and high-dose versus low-dose aspirin in individu- als undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233 43. 392. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment- elevation acute coronary syndromes. Circulation. 2001;104:2767 71. 393. O Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibi- tor in patients with acute coronary syndromes undergoing percutane- ous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel- Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009;54:678 85. 394. De Luca G, Cassetti E, Verdoia M, et al. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analyis of randomised trials. Thromb Haemost. 2009;102:428 36. 395. Lincoff AM, Bittl JA, Kleiman NS, et al. 